Molbio Diagnostics Limited

Molbio Diagnostics reported robust first-quarter results, demonstrating significant revenue and profit growth following its recent IPO. The company achieved ₹408 crore in revenue and a net profit of ₹52.7 crore, a substantial improvement from losses in the prior year, driven by increased test kit sales and operating leverage. Management anticipates continued momentum, projecting approximately 25% revenue growth and a 24-25% EBITDA margin for the full fiscal year, while also expanding its test menu and pursuing regulatory approvals for new diagnostic solutions like its HPV test. These developments suggest Molbio is well-positioned to capitalize on growing demand for rapid and accurate diagnostics, particularly within India’s national healthcare programs.